This second volume of Strategic Patent and Commercialization Journey of Nemonoxacin examines the molecule's progression through the most consequential stages of its development. Moving from late‑phase clinical evaluation to regulatory negotiation, manufacturing scale‑up, and early post‑approval deployment, the narrative situates Nemonoxacin within the broader scientific and policy environment shaping antimicrobial innovation. Central to this account is TaiGen's systematic construction of a durable intellectual property and life‑cycle management strategy. Through data‑driven patent generation, jurisdiction‑specific protection plans, and targeted extensions of clinical and formulation claims, the company sought to secure long‑term market viability in a competitive therapeutic domain. Set against shifting regional politics and Taiwan's growing biotech ambitions, this volume offers a close, unvarnished look at how a medicine survives the long arc from development to market - and how a company uses every lever available, from clinical evidence to life‑cycle management, to keep that arc intact. For readers interested in the human and strategic story behind drug development, it is both a case study and a record of a pivotal moment in Taiwan's scientific history.